Raffaella Vecchione
University of Naples Federico II
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Raffaella Vecchione.
Hepatology | 2007
Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Hepatocellular nodules in cirrhosis include regenerative (large regenerative, LRN) and dysplastic (low and high grade, LGDN and HGDN) nodules, early and grade 1 HCC (eHCC‐G1), and overt HCC. The differential diagnosis may be particularly difficult when lesions such as HGDN and eHCC‐G1 are involved. We investigated the diagnostic yield of a panel of 3 putative markers of hepatocellular malignancy such as HSP70, glypican 3 (GPC3), and glutamine synthetase (GS). We selected 52 surgically removed nonmalignant nodules (15 LRNs, 15 LGDNs, 22 HGDNs) and 53 HCCs (10 early, 22 grade 1, and 21 grade 2‐3) and immunostained them for HSP70, GPC3, and GS. The sensitivity and specificity of the individual markers for the detection of eHCC‐G1 were 59% and 86% for GS, 69% and 91% for GPC3, and 78% and 95% for HSP70. We identified 2 main phenotypes: (1) all negative, seen in 100% LRN and LGDN, 73% HGDN and 3% eHCC‐G1; (2) all positive, a feature detected in less than half the eHCC‐G1. Using a 3‐marker panel, when at least 2 of them, regardless which, were positive, the sensitivity and specificity for the detection of eHCC‐G1 were respectively 72% and 100%; the most sensitive combination was HSP70+/GPC3+ (59%) when a 2‐marker panel was used. Conclusion: The adopted panel of 3 markers is very helpful in distinguishing eHCC‐G1 from dysplastic nodules arising in cirrhosis. (HEPATOLOGY 2007;45:725–734.)
Journal of Hepatology | 2001
Carmela Loguercio; Vincenzo De Girolamo; Ilario de Sio; Concetta Tuccillo; Antonio Ascione; Feliciano Baldi; Gabriele Budillon; Lucia Cimino; Antonio Di Carlo; Maria Marino; F. Morisco; F.P. Picciotto; Luigi Terracciano; Raffaella Vecchione; Veronica Verde; Camillo Del Vecchio Blanco
BACKGROUND/AIMS Studies on non-alcoholic fatty liver disease (NAFLD) have included chronic liver damage attributed to various causes. Our investigation was held to observe the main clinical, histological, and pathophysiological aspects of NAFLD in patients not exposed to any known cause of chronic liver disease. METHODS We evaluated, in 84 in-patients (male/female, 66/18; median age, 36 years), the clinical and biochemical characteristics of NAFLD, and particularly its association with diabetes, dyslipidemia, hyperinsulinemia and/or with the increase of parameters of oxidative stress (blood levels of malonyldialdehyde, 4-hydroxynonenal and total plasma antioxidant capacity). RESULTS Ninety percent of patients had an increased body mass index (BMI), 35% had dyslipidemia, 40% had sub-clinical diabetes (only 3% had overt diabetes), 60% had hyperinsulinemia, and more than 90% had enhanced levels of lipid peroxidation markers. In 48 patients who had consented to liver biopsy, we found: 14 with simple steatosis, 32 with steatohepatitis, and two with cirrhosis. CONCLUSIONS Our data indicate that in our country, NAFLD may occur in young males with an increased BMI, with or without hyperinsulinemia, dyslipidemia and diabetes, generally associated with disorders of redox status, and that it may be differentiated from steatosis to steatohepatitis or cirrhosis only with a liver biopsy.
Clinical Infectious Diseases | 2005
Raffaele Iorio; Antonietta Giannattasio; Angela Sepe; Luigi Maria Terracciano; Raffaella Vecchione; Angela Vegnente
BACKGROUND The long-term outcome of chronic hepatitis C (CHC) has not been well studied, both for untreated and interferon-treated children. The aim of this study was to evaluate the long-term outcome of disease in a large series of children with CHC. METHODS Clinical, biochemical, virological, and histological features were evaluated in all children (age, 2-18 years) with CHC who did not have concomitant disease and who attended at our hospitals liver unit during the period of 1986-2004. RESULTS One hundred twenty-five children with CHC were studied. All patients remained free of symptoms throughout the period of observation. On the basis of transaminase levels during the first year of positivity for antibodies to hepatitis C virus (HCV), children were divided into 2 groups: patients with hypertransaminasemia (100 patients, all of whom had detectable HCV RNA), and those with normal transaminases (25 patients; 16 had viremia and 9 did not have viremia). Sustained clearance of viremia was achieved in 38% of the patients treated with interferon, compared with 12% of untreated children (P<.05). A sustained response to therapy was obtained in 64.7% of children infected with an HCV genotype other than genotype 1 and in 24.2% of those infected with HCV genotype 1 (P<.05). Histological lesions were mild in all 64 patients who underwent liver biopsy. No linear correlation was found between duration of disease and progression of fibrosis. Examination of a follow-up liver biopsy specimen revealed cirrhosis only in 1 (4.7%) of 21 children. CONCLUSIONS Children with CHC were symptom free and had a morphologically mild liver disease. Interferon therapy may be effective for patients infected with HCV genotypes other than genotype 1, whereas lower response rates are expected for HCV genotype 1-infected children. The real impact of therapy on long-term outcome remains to be established.
Journal of Viral Hepatitis | 2006
Marcello Persico; S. Perrotta; Eliana Persico; L. Terracciano; A. Folgori; L. Ruggeri; A. Nicosia; Raffaella Vecchione; Vincenzo La Mura; Mario Masarone; Roberto Torella
Summary. Some chronic hepatitis C (CHC) patients exhibit persistently normal alanine aminotransferase (ALT) levels (PNAL). Patients with PNAL experience significantly milder disease. In order to understand the differences between CHC patients with elevated ALT levels compared with those with PNAL better, we compared epidemiological, immunological and histological findings, in particular, the value of proliferating hepatocyte activity (PCNA) between the two groups of patients. We studied 40 chronic hepatitis C virus (HCV) carriers with increased ALT who underwent liver biopsy for histological diagnosis and determination of clinical prognosis, and 24 PNAL patients under follow‐up for 10 years. Immunological response to different HCV genomic epitopes was tested in both the control group and in PNAL subjects. PCNA values from liver specimens of all patients as well as liver biopsies of PNAL patients at time points 0 and 5 years were calculated according to Hall et al.Age, sex and body mass index (BMI) were not significantly different between the two groups. The median liver histology stage was significantly higher in HCV carriers vs the PNAL group (2.5, range = 2–6 vs 1.5, range = 1–2; P < 0.01). Among PNAL patients, histological stage was not statistically different at the three time points considered. Interferon (IFN)‐gamma production was comparable in the two groups. PCNA was significantly higher in the group with elevated ALT levels vs the PNAL group (8%, range = 4–15%vs 5% range = 3–8%; P < 0.05) and no statistically significant differences were found in PNAL patients at time points 0, 5 and 10 years. This study confirms that progression to cirrhosis is slow or absent in PNAL patients after 10 years of follow‐up. Accordingly, the hepatic proliferative activity index is low and seems to be stable over time.
Human Pathology | 2003
Luigi Terracciano; Barbara Bernasconi; Peter Ruck; Thomas Stallmach; Jakob Briner; Guido Sauter; Holger Moch; Raffaella Vecchione; Lucio Pollice; Guido Pettinato; Barbara Gürtl; Manfred Ratschek; Ronald R. de Krijger; Luigi Tornillo; Elisabeth Bruder
Hepatoblastoma (HB) is the most common liver tumor in childhood and differs in its environmental risk factors and genetic background from hepatocellular carcinoma. HB is associated with inherited conditions such as familial adenomatous polyposis and Beckwith-Wiedemann syndrome, suggesting the importance of genetic abnormalities in the pathogenesis and progression of this disease. It has a very polymorphous morphology. A diverse range of cytogenetic alterations has been reported to date, the most frequent being trisomy 2 and trisomy 20. Thirty-five HB specimens from 31 patients (22 purely epithelial, 4 purely mesenchymal, 9 mixed) were examined by comparative genomic hybridization (CGH), a technique that enables us to screen the entire tumor genome for genetic losses and gains. Our aims were as follows: (1) to characterize chromosome abnormalities that appear in this tumor and (2) to identify possible differences between different histologic subtypes of HB. We found significant gains of genetic material, with very little difference in the number and type of alterations between the different histologic components of HB. The most frequent alterations were gains of Xp (15 cases, 43%) and Xq (21 cases, 60%). This finding was also confirmed by fluorescent in situ hybridization performed on nuclei extracted from 6 specimens. Other common alterations were 1p-, 2q+, 2q-, 4q-, and 4q+. We found no difference between different histologic subtypes, a finding that may be in agreement with the hypothesis of a common clonal origin for the different components. An hitherto-unreported high frequency of X chromosome gains may support the assumption that X-linked genes are involved in the development of this neoplasm.
American Journal of Medical Genetics Part A | 2007
Massimiliano Rossi; Maria D'Armiento; Ida Parisi; Paola Ferrari; Christine M. Hall; Mariarosaria Cervasio; Francesco Rivasi; Fiorella Balli; Raffaella Vecchione; Gaetano Corso; Generoso Andria; Giancarlo Parenti
Lathosterolosis (LS) is a defect of cholesterol biosynthesis due to the deficiency of the enzyme sterol‐C5‐desaturase. Only two patients have been described to date, both presenting with multiple malformations, mental retardation, and liver involvement. In addition in one of them pathological examination revealed mucolipidosis‐like inclusions on optic microscopy analysis, and peculiar lysosomal lamellar bodies on electron microscopy analysis. This study is focused on a better characterization of the clinical phenotype of LS. We describe a further case in a fetus, sibling of the first patient reported, presenting with neural tube defect, craniofacial and limb anomalies, and prenatal liver involvement. The fetal phenotype suggests the possible occurrence of significant intrafamilial variability in LS, and expands the phenotypic spectrum of the disease. Histological examination of autopsy samples from the fetus and skin fibroblasts from the living sibling suggested that the mucolipidosis‐like picture previously reported is not a constant feature of LS, being possibly associated with the most severe biochemical defects, but confirmed the ultrastructural finding of lamellar inclusions. The LS phenotype appears to be characterized by the distinctive association of a recognizable pattern of congenital anomalies, involving axial and appendicular skeleton, liver, central nervous and urogenital systems, and lysosomal storage. This condition partially overlaps with other defects of sterol metabolism, suggesting intriguing pathogenic links among these conditions.
American Journal of Medical Genetics Part A | 2005
Massimiliano Rossi; Pietro Vajro; Raffaele Iorio; Antonella Battagliese; Nicola Brunetti-Pierri; Gaetano Corso; Maja Di Rocco; Paola Ferrari; Francesco Rivasi; Raffaella Vecchione; Generoso Andria; Giancarlo Parenti
Inborn defects of cholesterol biosynthesis are a group of metabolic disorders presenting with mental retardation and multiple congenital anomalies (MCA/MR syndromes). Functional and structural liver involvement has been reported as a rare (2.5–6%) complication of the Smith–Lemli–Opitz syndrome (SLOS) (OMIM: #270400) and it has not been fully characterized. Here, we report on a long‐term follow‐up study of four patients with SLOS, and one case with lathosterolosis (OMIM: #607330) who presented with liver disease and underwent an extensive diagnostic work‐up. Reports of liver involvement in cholesterol biosynthesis defects are reviewed. Two main different patterns of liver involvement emerged: progressive cholestasis, and stable isolated hypertransaminasemia. In our series, the first pattern was found in two patients with SLOS and one with lathosterolosis, and the second in two SLOS cases. Cholestasis was associated with early lethality and normal serum γ‐glutamyl‐transferase (GGT) levels in SLOS, while possible prolonged survival and high GGT levels were seen in lathosterolosis. Hepatic fibrosis was present in both conditions. Liver biopsy performed in one of our SLOS patients with isolated hypertransaminasemia, showed only mild hydropic degeneration of the hepatocytes. The presence of liver involvement in 16% of the SLOS patients diagnosed at our Center suggests that this complication might have been underestimated in previously reported cases, possibly overshadowed by the severity of multiple malformations. Fetal hepatopathy, cholestasis, and isolated hypertransaminasemia can occur also in other disorders of cholesterol biosynthesis, such as mevalonic aciduria (OMIM: +251170), desmosterolosis (OMIM: #602398), Conradi–Hünermann syndrome (OMIM: #302960), Greenberg dysplasia (OMIM: #215140), and Pelger–Huët homozygosity syndrome (#169400). This group of inherited disorders should be considered in the differential diagnosis of patients presenting with liver disease associated with developmental delay and/or multiple malformations. Periodic liver function evaluations are recommended in these patients.
American Journal of Clinical Pathology | 2000
Luigi Terracciano; Roselyn A. Patzina; Frank S. Lehmann; Luigi Tornillo; Gieri Cathomas; Paulette Mhawech; Raffaella Vecchione; Leonardo Bianchi
We retrospectively studied 42 liver biopsy specimens from 39 patients who met serologic and histologic criteria of autoimmune liver diseases. We found 10 cases of overlap syndrome (OLS), 10 autoimmune cholangitis (AIC), 10 primary biliary cirrhosis (PBC), and 9 autoimmune hepatitis (AIH) type 1. The following results were obtained: (1) Granulomas and biliary duct lesions were more prominent in PBC and AIC than in OLS and AIH. (2) Bile duct loss was not observed in AIH cases. (3) Features of hepatocellular damage such as piecemeal necrosis, spotty lobular necrosis, and confluent necrosis, were much more prevalent in OLS and AIH than in PBC and AIC. (4) HLA-DR antigen expression by hepatocytes was more frequent in AIH and OLS, whereas the expression of the same antigen by the bile duct epithelium was more frequent in PBC and AIC. We conclude there is a morphologic spectrum in autoimmune liver diseases, in which PBC forms one end of the spectrum, AIH the other, OLS the middle but closer clinically and histologically to AIH than to PBC, and AIC, which seems to be an antimitochondrial antibody-negative subtype of PBC.
Journal of Pediatric Gastroenterology and Nutrition | 2003
Raffaele Iorio; Mariangela D'ambrosi; Giuseppina Mazzarella; Flavia Varrella; Raffaella Vecchione; Angela Vegnente
Wilson disease (WD) is an inherited autosomal recessive disorder of copper accumulation that is fatal unless detected and treated. Mutations of the gene responsible for WD (ATP7B) lead to failure of copper excretion in the bile. The genetic defect results in accumulation and toxicity of copper primarily in the liver and then in extrahepatic sites, such as the brain, eyes, kidneys, erythrocytes, and skeletal system (1). The age at onset and the manifestations of WD may vary markedly from one patient to another. A patient with WD may seek treatment for hepatic, neurologic, psychiatric, hematologic, renal, or skeletal symptoms; some patients are diagnosed presymptomatically by familial screening (2). Unexplained hypertransaminasemia not associated with clinical signs of liver disease is not usually reported among presentation modes of WD (1,2). It is of note that practically all patients with WD remain asymptomatic for their first 3 years of life (3) and that WD usually appears with evidence of liver damage during childhood, while symptoms related to neurologic or psychiatric disease tend to appear during adolescence or early adult life (2). Early diagnosis is mandatory so that therapy can be started before hepatocellular damage is irreversible and to prevent brain damage. Although zinc is universally accepted as elective therapy for presymptomatic children, how early to start therapy is an open question. We report the case of a child with very early onset of WD, in whom hypertransaminasemia occurred at age 13 months and zinc therapy achieved a prompt normalization of liver enzymes.
The Journal of Pediatrics | 2011
Roberta Buonavolontà; Erasmo Miele; Daniela Russo; Raffaella Vecchione; Annamaria Staiano
OBJECTIVE To evaluate the efficacy of triple eradication therapy versus symptomatic therapy in children with Helicobacter pylori-associated chronic active gastritis (H pylori-ACAG). STUDY DESIGN Symptomatic patients with H pylori-ACAG (n=31) were randomly assigned into two groups: (1) patients infected with H pylori who were treated with triple eradication therapy (n = 16); and (2) patients infected with H pylori who were treated with symptomatic therapy (n=15). RESULTS After 1 year of follow-up, macroscopic appearance was significantly different in group B (P=.023), and chronic inflammation, H Pylori density, and activity were significantly higher in group B than in group A (P=.022, .007, and .002, respectively); however, we did not find a significant difference in the symptoms comparing both groups (P=.287). After 1 year of follow-up, we observed the persistence of the H pylori infection in all children who had not received eradication treatment. CONCLUSIONS There is no correlation between eradication of H pylori infection and improvement of dyspeptic symptoms. Self-eradication does not occur within 1 year of follow-up. A trend toward a higher rate of chronic inflammation in noneradicated children at 1 year limited the time of our study.